Bank of New York Mellon’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-601,414
| Closed | -$212K | – | 4395 |
|
|
2016
Q3 | $212K | Sell |
601,414
-47,902
| -7% | -$16.9K | ﹤0.01% | 3880 |
|
|
2016
Q2 | $303K | Buy |
649,316
+32,290
| +5% | +$15.1K | ﹤0.01% | 3742 |
|
|
2016
Q1 | $839K | Buy |
617,026
+53,624
| +10% | +$72.9K | ﹤0.01% | 3171 |
|
|
2015
Q4 | $828K | Sell |
563,402
-25,336
| -4% | -$37.2K | ﹤0.01% | 3284 |
|
|
2015
Q3 | $930K | Sell |
588,738
-90,602
| -13% | -$143K | ﹤0.01% | 3228 |
|
|
2015
Q2 | $1.16M | Buy |
679,340
+60,413
| +10% | +$103K | ﹤0.01% | 3252 |
|
|
2015
Q1 | $860K | Buy |
618,927
+60,007
| +11% | +$83.4K | ﹤0.01% | 3384 |
|
|
2014
Q4 | $845K | Sell |
558,920
-30,096
| -5% | -$45.5K | ﹤0.01% | 3400 |
|
|
2014
Q3 | $1.21M | Sell |
589,016
-22,188
| -4% | -$45.7K | ﹤0.01% | 3180 |
|
|
2014
Q2 | $1.87M | Buy |
611,204
+55,853
| +10% | +$171K | ﹤0.01% | 2938 |
|
|
2014
Q1 | $1.39M | Buy |
555,351
+29,293
| +6% | +$73.3K | ﹤0.01% | 3114 |
|
|
2013
Q4 | $2.61M | Buy |
526,058
+74,505
| +16% | +$370K | ﹤0.01% | 2719 |
|
|
2013
Q3 | $1.03M | Buy |
451,553
+49,446
| +12% | +$113K | ﹤0.01% | 3233 |
|
|
2013
Q2 | $892K | Buy |
+402,107
| New | +$892K | ﹤0.01% | 3248 |
|
Bank of New York Mellon's RXII Position: Q4 2016 in Review
Bank of New York Mellon sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 601,414 shares — an estimated $212K sold.
Bank of New York Mellon first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $2.61M in Q4 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- Bank of New York Mellon reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- Bank of New York Mellon sold 601,414 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $212K.
- Bank of New York Mellon first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
- Bank of New York Mellon's GALENA BIOPHARMA INC COM position peaked at $2.61M in Q4 2013.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on Bank of New York Mellon's 13F filing for Q4 2016, filed 13 Feb 2017.